Oral tablet
Phase 2Initiated per sponsor
← Therapy pipeline
Investigational · Obesity development
Amylin 355 (NN9638)
NN9638 · Novo Nordisk
An amylin program with separate oral and subcutaneous development.
amylin
Obesity stagePhase 2
Phase 1Phase 2Phase 3Regulatory review
Updated as of November 2026SponsorNovo Nordisk
Targetsamylin
RouteOral tablet + Injection
DevelopmentFormulations differ
Results availability
No numerical results shown
Phase 2 clinical efficacy results are pending.
Mechanism at a glance
GLP-1GLP-1—
GIPGIP—
GCGglucagon—
AMYamylinTargeted
OTHOther targets—
Obesity stage by formulation
Injection
Phase 2Initiated per sponsor
Milestone → next
Latest: Novo Nordisk’s November 4, 2026 presentation reports Phase 2 initiation for oral and subcutaneous Amylin 355.
Next: Phase 2 trial details and clinical efficacy results.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies2 records
Amylin 355 · oral Phase 2 program
Weight managementStudy: Initiated per sponsorResults: Phase 2 results pending; sponsor initiation announcementStatus reviewed November 2026
Sponsor presentation describes a 170-participant, 26-week oral placebo-controlled study; Phase 2 protocol identifier not verified.
Amylin 355 · subcutaneous Phase 2 program
Weight managementStudy: Initiated per sponsorResults: Phase 2 results pending; sponsor initiation announcementStatus reviewed November 2026
Sponsor reports Phase 2 initiation for the subcutaneous formulation; detailed protocol identifier not verified.